465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This review underscores the rapid evolution of pharmacotherapy for obesity, moving beyond traditional approaches to highly effective hormonal analogues that mimic natural satiety signals. The findings suggest a future…
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This review critically underscores the importance of a holistic and integrated approach to weight management when utilizing powerful pharmacological tools like GLP-1 RAs. Preserving muscle mass is not merely an aesthe…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
This systematic review provides compelling evidence that next-generation incretin agonists offer superior efficacy for both weight management and glycemic control in overweight and obese individuals. The substantial w…
The findings from this study are profoundly significant, as they identify retatrutide as a potentially superior therapeutic agent for MC4R-deficient obesity, a condition notoriously difficult to manage. This MC4R defi…
This research highlights a critical public health concern stemming from the proliferation of unregulated compounded GLP-1 RAs sold directly to consumers. The findings underscore the substantial potential for patient s…
While the detailed quantitative results from this completed clinical trial are not yet publicly available in this record, the study successfully concluded its primary objective of assessing Tirzepatide's influence on …
The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with b…
The systematic review consistently demonstrated that tirzepatide led to significant and dose-dependent reductions in body weight across various populations, including individuals with obesity and those with type 2 dia…
This case report highlights the potential of combination therapy with Tirzepatide and metformin as a highly effective intervention for MC4R deficiency-induced severe obesity and hyperphagia. The significant reductions…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…